BAJAJ BROKING

Notification
No new Notification messages
Inventurus Knowledge Solutions IPO is Open!
Apply for the Inventurus Knowledge Solutions IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
jagsonpal pharmaceuticals stock

JAGSONPAL PHARMACEUTICALS Share Price

672.45 9.54 (1.43%)
Dec 13 2024 03:30 PM Pharmaceuticals NSE: JAGSNPHARM

JAGSONPAL PHARMACEUTICALS Share Price Update

As of the latest trading session, JAGSONPAL PHARMACEUTICALS share price is currently at 672.45, which is up by 9.54 from its previous closing. Today, the stock has fluctuated between 647.45 and 679.00. Over the past year, JAGSONPAL PHARMACEUTICALS has achieved a return of 66.94 %. In the last month alone, the return has been 26.40 %. Read More...

JAGSONPAL PHARMACEUTICALS Performance

Day Range

Low647.45 High679.00
672.45

52 Week Range

Low 273.60 High 820.10
672.45

JAGSONPAL PHARMACEUTICALS Share Price

4410

507789

JAGSNPHARM

img img img img
No Data Available

Open Price

660.00

Prev. Close

662.90

Volume (Shares)

95436.00

Total traded value

641.75

Upper Circuit

795.45

Lower Circuit

530.35

Note: The current prices & values are delayed, Login to your account for live updates.

JAGSONPAL PHARMACEUTICALS Fundamentals


(Standalone)

Market Cap (Cr) 1785.10
PE Ratio (TTM) 73.72
Book Value / Share 74.26
Beta 1.11
ROE 12.97%
EPS (TTM) 10.08
Dividend Yield 0.74%
Net Profit Qtr (Cr) 11.46

JAGSONPAL PHARMACEUTICALS Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars SEP 2024 (Values in Cr)
Revenue 74.69
Operating Expense 60.98
Net Profit 11.46
Net Profit Margin (%) 15.34
Earnings Per Share (EPS) 4.29
EBITDA 17.93
Effective Tax Rate (%) 25.43
Particulars JUN 2024 (Values in Cr)
Revenue 61.44
Operating Expense 52.49
Net Profit 5.33
Net Profit Margin (%) 8.67
Earnings Per Share (EPS) 1.94
EBITDA 8.40
Effective Tax Rate (%) 25.03
Particulars MAR 2024 (Values in Cr)
Revenue 43.49
Operating Expense 41.44
Net Profit 3.55
Net Profit Margin (%) 8.16
Earnings Per Share (EPS) 1.31
EBITDA 5.16
Effective Tax Rate (%) 21.80
Particulars DEC 2023 (Values in Cr)
Revenue 47.23
Operating Expense 44.48
Net Profit 3.96
Net Profit Margin (%) 8.38
Earnings Per Share (EPS) 1.48
EBITDA 5.92
Effective Tax Rate (%) 25.00
Particulars SEP 2023 (Values in Cr)
Revenue 57.83
Operating Expense 50.14
Net Profit 7.47
Net Profit Margin (%) 12.91
Earnings Per Share (EPS) 2.84
EBITDA 10.64
Effective Tax Rate (%) 25.00
Particulars MAR 2024 (Values in Cr)
Revenue 208.70
Operating Expense 188.11
Net Profit 22.46
Net Profit Margin (%) 10.76
Earnings Per Share (EPS) 8.49
EBITDA 32.33
Effective Tax Rate (%) 24.80
Particulars MAR 2023 (Values in Cr)
Revenue 236.71
Operating Expense 204.18
Net Profit 26.72
Net Profit Margin (%) 11.28
Earnings Per Share (EPS) 10.20
EBITDA 36.43
Effective Tax Rate (%) 23.24
Particulars MAR 2022 (Values in Cr)
Revenue 217.58
Operating Expense 194.37
Net Profit 18.86
Net Profit Margin (%) 8.66
Earnings Per Share (EPS) 7.20
EBITDA 28.46
Effective Tax Rate (%) 29.24
Particulars MAR 2021 (Values in Cr)
Revenue 187.95
Operating Expense 170.45
Net Profit 17.06
Net Profit Margin (%) 9.07
Earnings Per Share (EPS) 6.51
EBITDA 23.47
Effective Tax Rate (%) 21.99
Particulars MAR 2020 (Values in Cr)
Revenue 158.57
Operating Expense 151.67
Net Profit 7.87
Net Profit Margin (%) 4.96
Earnings Per Share (EPS) 3.00
EBITDA 11.05
Effective Tax Rate (%) 16.36
Particulars MAR 2024 (Values in Cr)
Book Value / Share 70.88
ROE % 12.97
ROCE % 16.89
Total Debt to Total Equity 0.04
EBITDA Margin 15.50
Particulars MAR 2023 (Values in Cr)
Book Value / Share 60.65
ROE % 18.32
ROCE % 23.48
Total Debt to Total Equity 0.02
EBITDA Margin 15.39
Particulars MAR 2022 (Values in Cr)
Book Value / Share 50.68
ROE % 15.28
ROCE % 21.14
Total Debt to Total Equity 0.03
EBITDA Margin 13.08
Particulars MAR 2021 (Values in Cr)
Book Value / Share 43.55
ROE % 15.70
ROCE % 19.57
Total Debt to Total Equity 0.05
EBITDA Margin 12.49
Particulars MAR 2020 (Values in Cr)
Book Value / Share 39.39
ROE % 7.88
ROCE % 9.53
Total Debt to Total Equity 0.04
EBITDA Margin 6.97
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 147.93
Total Assets 217.07
Total Liabilities 217.07
Total Equity 187.40
Share Outstanding 26437794
Price to Book Ratio 3.95
Return on Assets (%) 10.34
Return on Capital (%) 11.99
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 114.62
Total Assets 194.94
Total Liabilities 194.94
Total Equity 158.89
Share Outstanding 26198000
Price to Book Ratio 4.78
Return on Assets (%) 13.70
Return on Capital (%) 16.82
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 25.24
Total Assets 164.22
Total Liabilities 164.22
Total Equity 132.75
Share Outstanding 26198000
Price to Book Ratio 6.19
Return on Assets (%) 11.48
Return on Capital (%) 14.2
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 60.22
Total Assets 164.20
Total Liabilities 164.20
Total Equity 121.92
Share Outstanding 26198000
Price to Book Ratio 1.83
Return on Assets (%) 10.38
Return on Capital (%) 13.25
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 38.07
Total Assets 146.95
Total Liabilities 146.95
Total Equity 111.03
Share Outstanding 26198000
Price to Book Ratio 0.44
Return on Assets (%) 5.35
Return on Capital (%) 6.8
Particulars MAR 2024 (Values in Cr)
Net Income 29.86
Cash from Operations 43.67
Cash from Investing -24.54
Cash from Financing -8.91
Net change in Cash 1.70
Free Cash Flow 43.92
Particulars MAR 2023 (Values in Cr)
Net Income 34.80
Cash from Operations 53.93
Cash from Investing -57.67
Cash from Financing -0.45
Net change in Cash -11.47
Free Cash Flow 54.24
Particulars MAR 2022 (Values in Cr)
Net Income 26.64
Cash from Operations 13.78
Cash from Investing -25.77
Cash from Financing -17.55
Net change in Cash -36.41
Free Cash Flow 14.83
Particulars MAR 2021 (Values in Cr)
Net Income 21.87
Cash from Operations 31.37
Cash from Investing -2.26
Cash from Financing -6.82
Net change in Cash 19.12
Free Cash Flow 31.84
Particulars MAR 2020 (Values in Cr)
Net Income 9.41
Cash from Operations 12.81
Cash from Investing -10.76
Cash from Financing -0.94
Net change in Cash -0.46
Free Cash Flow 14.88
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 64.13 36.86 3.50 491.45 37.54 / 77.70
BLISS GVS PHARMA LTD 175.85 22.01 1.83 1852.87 92.25 / 179.65
CIPLA LTD 1447.35 25.32 4.12 116889.80 1192.85 / 1702.00
FERMENTA BIOTECH LIMITED 403.70 140.17 4.09 1188.13 145.00 / 440.00
GLAXOSMITHKLINE PHARMA LT 2254.45 47.63 22.83 38191.74 1668.20 / 3087.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 64.13 55.77 10.90 491.45 37.54 / 77.70
AMRUTAJAN HEALTH LTD 749.90 45.61 7.28 2168.01 556.05 / 861.40
ASTRAZENECA PHARMA IND LT 6603.60 128.25 24.30 16509.00 4050.15 / 8139.85
BLISS GVS PHARMA LTD 175.85 22.93 1.80 1852.87 92.25 / 179.65

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 672.80
  • 26 Days 657.60
  • 10 Days 690.90
  • 50 Days 589.50
  • 12 Days 682.70
  • 100 Days 512.60
  • 20 Days 657.90
  • 200 Days 329.20
668.25
PIVOT
First Resistance 676.60
Second Resistance 690.30
Third Resistance 698.65
First Support 654.55
Second Support 646.20
Third Support 632.50
RSI 56.78
MACD 25.05
Commodity Channel Index (CCI) -3.20
ADX 53.32
Williams % R -85.52

Over 1 Month

down

26.40

Over 3 Months

down

64.95

Over 6 Months

down

96.76

Over 1 Year

down

66.94

Over 3 Years

down

59.84

Over 5 Years

down

93.95

JAGSONPAL PHARMACEUTICALS Future

Future: Price

25 May
0 100 200 300 400 500 600

Discount/Premium

25 May
0 1 2 3 4 5 6 7

Active Calls

25 May
0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul
0 500 1000 1500 2000 2500

JAGSONPAL PHARMACEUTICALS Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Public
29.61
Promoter Holdings
67.97
FII
2.29
DII
0.11
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Aresko Progressive Private Limited Shareholding of Promoter and Promoter Group 5334254.0 20.14
Infinity Holdings Sidecar I Shareholding of Promoter and Promoter Group 4755300.0 17.95
Infinity Holdings Shareholding of Promoter and Promoter Group 4413020.0 16.66
Infinity Portfolio Holdings Shareholding of Promoter and Promoter Group 2287180.0 8.64
Rajpal Singh Kochhar Shareholding of Promoter and Promoter Group 1212160.0 4.58
Manish Gupta Public Shareholding 632604.0 2.39
Mukul Mahavir Agrawal Public Shareholding 463023.0 1.75
Authum Investment And Infrastructure Limited Public Shareholding 387186.0 1.46
Sanjiv Kumar Dudeja Public Shareholding 370544.0 1.4
Lincoln P Coelho Public Shareholding 310200.0 1.17

JAGSONPAL PHARMACEUTICALS

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2023-08-21 5.0 Final 2023-08-21 Equity shares 2021-10-29 4.0 Interim 2021-11-01 Equity shares 2021-09-22 1.0 Final 2021-09-24 Equity shares 2020-09-22 0.5 Final 2020-09-24 Equity shares 2019-09-20 0.25 Final 2019-09-24 Equity shares 2018-09-18 0.1 Final 2018-09-21 Equity shares 2017-09-21 0.1 Final 2017-09-23 Equity shares 2016-09-21 0.1 Final 2016-09-23 Equity shares 2015-09-21 0.1 Final 2015-09-23 Equity shares 2014-09-25 0.5 Final 2014-09-27 Equity shares 2013-09-25 0.5 Final 2013-09-27 Equity shares 2012-09-21 5.0 Final 2012-09-25 Equity shares 2011-09-23 0.5 Final 2011-09-27 Equity shares 2010-09-21 0.5 Final 2010-09-23 Equity shares 2009-09-23 0.25 Final 2009-09-25 Equity shares 2008-09-24 0.1 Final 2008-09-26 Equity shares 2007-09-21 0.1 Final 2007-09-25 Equity shares 2005-09-26 0.0 Final 2005-09-28 Equity shares
Ex-Date Ex-Bonus Ratio
2004-07-28 2004-07-20 3:1
Ex-Date Old FV NEW FV Record Date
2004-07-20 10.0 5.0 2004-07-28

Learn More About Stocks

About JAGSONPAL PHARMACEUTICALS

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by JAGSONPAL PHARMACEUTICALS

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Jagsonpal Pharmaceuticals Ltd?

Answer Field

The share price of Jagsonpal Pharmaceuticals Ltd for NSE is ₹ 672.45 and for BSE is ₹ 673.05.

What is the Market Cap of Jagsonpal Pharmaceuticals Ltd?

Answer Field

The market cap of Jagsonpal Pharmaceuticals Ltd for NSE is ₹ 17,85.10 Cr. and for BSE is ₹ 0.0 Cr. as of now.

What is the 52 Week High and Low of Jagsonpal Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Jagsonpal Pharmaceuticals Ltd for NSE is ₹ 820.10 and ₹ 273.60 and for BSE is ₹ 820.05 and ₹ 270.05.

How to Buy Jagsonpal Pharmaceuticals Ltd share?

Answer Field

You can trade in Jagsonpal Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Jagsonpal Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 66.94%.

What is the Current Share Price of Jagsonpal Pharmaceuticals Ltd?

Answer Field

Jagsonpal Pharmaceuticals Ltd share price is for NSE ₹ 672.45 & for BSE ₹ 673.05 as on Dec 13 2024 03:30 PM.

What is the Market Cap of Jagsonpal Pharmaceuticals Ltd Share?

Answer Field

The market cap of Jagsonpal Pharmaceuticals Ltd for NSE ₹ 17,85.10 & for BSE ₹ 0.0 as on Dec 13 2024 03:30 PM.

What is the P/E Ratio of Jagsonpal Pharmaceuticals Ltd Share?

Answer Field

As on Dec 13 2024 03:30 PM the price-to-earnings (PE) ratio for Jagsonpal Pharmaceuticals Ltd share is 73.72.

What is the PB ratio of Jagsonpal Pharmaceuticals Ltd Share?

Answer Field

As on Dec 13 2024 03:30 PM, the price-to-book (PB) ratio for Jagsonpal Pharmaceuticals Ltd share is 74.26.

How to Buy Jagsonpal Pharmaceuticals Ltd Share?

Answer Field

You can trade in Jagsonpal Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Jagsonpal Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Jagsonpal Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Jagsonpal Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4700+ Cr MTF Book

icon-with-text
loader